Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:APLS NASDAQ:LGND OTCMKTS:PHGUF NASDAQ:TLX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPLSApellis Pharmaceuticals$28.17+2.2%$22.16$16.10▼$41.94$3.56B0.732.28 million shs1.92 million shsLGNDLigand Pharmaceuticals$163.73+1.2%$136.85$93.58▼$164.67$3.21B0.96147,944 shs147,257 shsPHGUFPharming Group$1.37+5.4%$1.17$0.75▼$1.37$919.37M0.659,009 shs10,900 shsTLXTelix Pharmaceuticals$9.43-1.3%$13.78$9.25▼$30.36$3.19BN/A58,770 shs282,323 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPLSApellis Pharmaceuticals0.00%+0.18%+20.13%+46.49%-29.13%LGNDLigand Pharmaceuticals0.00%+1.84%+21.84%+58.00%+52.84%PHGUFPharming Group0.00%0.00%+13.04%+30.00%+57.59%TLXTelix Pharmaceuticals0.00%-21.72%-26.82%-43.72%+954,999,900.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAPLSApellis Pharmaceuticals4.2044 of 5 stars3.33.00.04.42.32.50.6LGNDLigand Pharmaceuticals3.5245 of 5 stars1.51.00.04.43.42.51.9PHGUFPharming GroupN/AN/AN/AN/AN/AN/AN/AN/ATLXTelix PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAPLSApellis Pharmaceuticals 2.58Moderate Buy$34.1221.11% UpsideLGNDLigand Pharmaceuticals 3.00Buy$171.834.95% UpsidePHGUFPharming Group 0.00N/AN/AN/ATLXTelix Pharmaceuticals 2.80Moderate Buy$22.33136.83% UpsideCurrent Analyst Ratings BreakdownLatest PHGUF, APLS, TLX, and LGND Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/2/2025LGNDLigand PharmaceuticalsBenchmarkSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$160.00 ➝ $175.008/28/2025LGNDLigand PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$157.00 ➝ $206.008/28/2025TLXTelix PharmaceuticalsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Neutral8/28/2025TLXTelix PharmaceuticalsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$22.008/8/2025LGNDLigand PharmaceuticalsRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$155.00 ➝ $185.008/4/2025APLSApellis PharmaceuticalsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$35.00 ➝ $37.008/1/2025APLSApellis PharmaceuticalsRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetSector Perform ➝ Sector Perform$17.00 ➝ $19.008/1/2025APLSApellis PharmaceuticalsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$39.00 ➝ $40.008/1/2025APLSApellis PharmaceuticalsRaymond James FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$52.00 ➝ $50.007/30/2025LGNDLigand PharmaceuticalsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$145.00 ➝ $162.007/29/2025APLSApellis PharmaceuticalsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$41.00 ➝ $46.00(Data available from 9/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAPLSApellis Pharmaceuticals$781.37M4.55N/AN/A$1.84 per share15.31LGNDLigand Pharmaceuticals$167.13M19.20$1.63 per share100.64$43.95 per share3.73PHGUFPharming Group$297.20M3.09N/AN/A$0.33 per share4.15TLXTelix Pharmaceuticals$637.77M5.00$0.11 per share83.63$1.12 per share8.42Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAPLSApellis Pharmaceuticals-$197.88M-$1.82N/AN/AN/A-30.24%-116.09%-26.72%11/4/2025 (Estimated)LGNDLigand Pharmaceuticals-$4.03M-$4.00N/A44.13N/A-40.44%-9.21%-8.09%11/6/2025 (Estimated)PHGUFPharming Group-$11.84MN/A0.00∞N/A-2.19%-3.31%-1.78%11/6/2025 (Estimated)TLXTelix Pharmaceuticals$32.93MN/A0.0019.65N/AN/AN/AN/AN/ALatest PHGUF, APLS, TLX, and LGND EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/7/2025Q2 2025LGNDLigand Pharmaceuticals$1.54$1.60+$0.06$0.24$43.87 million$47.63 million7/31/2025Q2 2025APLSApellis Pharmaceuticals-$0.44-$0.33+$0.11-$0.33$187.91 million$171.39 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAPLSApellis PharmaceuticalsN/AN/AN/AN/AN/ALGNDLigand PharmaceuticalsN/AN/AN/AN/AN/APHGUFPharming GroupN/AN/AN/AN/AN/ATLXTelix PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAPLSApellis Pharmaceuticals2.903.773.16LGNDLigand PharmaceuticalsN/A5.455.21PHGUFPharming Group0.502.792.07TLXTelix Pharmaceuticals0.992.782.66Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAPLSApellis Pharmaceuticals96.29%LGNDLigand Pharmaceuticals91.28%PHGUFPharming GroupN/ATLXTelix PharmaceuticalsN/AInsider OwnershipCompanyInsider OwnershipAPLSApellis Pharmaceuticals6.80%LGNDLigand Pharmaceuticals7.00%PHGUFPharming GroupN/ATLXTelix PharmaceuticalsN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAPLSApellis Pharmaceuticals770126.29 million117.70 millionOptionableLGNDLigand Pharmaceuticals8019.60 million18.23 millionOptionablePHGUFPharming Group382671.07 millionN/ANot OptionableTLXTelix PharmaceuticalsN/A338.40 millionN/AN/APHGUF, APLS, TLX, and LGND HeadlinesRecent News About These CompaniesTelix Pharmaceuticals (ASX:TLX) Falls 24% in a Week After FDA Complete Response Letter4 hours ago | finance.yahoo.comFY2026 Earnings Forecast for TLX Issued By William BlairSeptember 2 at 2:02 AM | marketbeat.comResearch Analysts Set Expectations for TLX FY2026 EarningsSeptember 2 at 2:43 AM | americanbankingnews.comTelix Pharmaceuticals (NASDAQ:TLX) Shares Gap Down - Here's WhyAugust 31 at 11:44 AM | marketbeat.comWilliam Blair Has Bearish Estimate for TLX FY2027 EarningsAugust 31 at 6:30 AM | marketbeat.comWedbush Analysts Decrease Earnings Estimates for TLXAugust 31 at 5:38 AM | marketbeat.comWilliam Blair Has Pessimistic View of TLX FY2027 EarningsAugust 31 at 2:54 AM | americanbankingnews.comFY2025 EPS Estimate for Telix Pharmaceuticals Cut by AnalystAugust 31 at 2:21 AM | americanbankingnews.comTelix Pharmaceuticals (NASDAQ:TLX) Reaches New 12-Month Low - Here's What HappenedAugust 30 at 12:13 PM | marketbeat.comTelix Pharmaceuticals (NASDAQ:TLX) Earns "Outperform" Rating from WedbushAugust 30 at 9:33 AM | marketbeat.comWedbush Reiterates "Outperform" Rating for Telix Pharmaceuticals (NASDAQ:TLX)August 30 at 2:43 AM | americanbankingnews.comTelix Pharmaceuticals Limited (TLX) Hits Another Roadblock After SEC Subpoena, Shares Fall Again -- Hagens BermanAugust 29, 2025 | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Telix Pharmaceuticals Limited – TLXAugust 29, 2025 | globenewswire.comHealth Check: Angry investors birch Telix shares after third US regulatory setbackAugust 29, 2025 | msn.comTelix Pharmaceuticals' (TLX) "Neutral" Rating Reaffirmed at JPMorgan Chase & Co.August 29, 2025 | americanbankingnews.comAustralia's Telix Pharma says FDA seeks more data on cancer diagnostic drug; shares plungeAugust 28, 2025 | msn.comTelix shares just crashed 24%! Here's whyAugust 28, 2025 | msn.comUS FDA seeks more information on Telix Pharma's diagnostic drug for kidney cancerAugust 27, 2025 | reuters.comTelix Pharmaceuticals (NASDAQ:TLX) Sees Unusually-High Trading Volume - What's Next?August 27, 2025 | marketbeat.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Telix Pharmaceuticals Limited - TLXAugust 27, 2025 | prnewswire.comTelix Pharmaceuticals Limited (TLX) Shares Fall Amid SEC Subpoena -- Hagens BermanAugust 26, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimePHGUF, APLS, TLX, and LGND Company DescriptionsApellis Pharmaceuticals NASDAQ:APLS$28.17 +0.60 (+2.18%) Closing price 04:00 PM EasternExtended Trading$27.82 -0.36 (-1.26%) As of 05:21 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops APL-3007, a small interfering RNA, or siRNA, which is in a Phase 1 clinical trial, as well as an oral complement inhibitor that is in preclinical development. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.Ligand Pharmaceuticals NASDAQ:LGND$163.73 +2.02 (+1.25%) Closing price 04:00 PM EasternExtended Trading$163.62 -0.11 (-0.07%) As of 04:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Filspari, a dual endothelin and angiotensin II receptor antagonist in development for rare kidney diseases and non-immunosuppressive treatment indicated for immunoglobulin A nephropathy; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and children aged 8 years and older with Stage 2 T1D; Nexterone, a captisol-enabled formulation of amiodarone; Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression; and Veklury, an antiviral treatment for moderate or severe COVID-19. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of post-menopausal symptoms in women; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta and Zybev for various indications. The company has alliances, licenses, and other business relationships with Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences, and Baxter International. Further, it sells Captisol materials. Ligand Pharmaceuticals Incorporated was incorporated in 1987 and is based in Jupiter, Florida.Pharming Group OTCMKTS:PHGUF$1.37 +0.07 (+5.38%) As of 01:13 PM EasternPharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.Telix Pharmaceuticals NASDAQ:TLX$9.43 -0.12 (-1.26%) Closing price 04:00 PM EasternExtended Trading$9.51 +0.08 (+0.80%) As of 05:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Telix Pharmaceuticals Limited. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals. The Product Development segment develops radiopharmaceutical products for commercialization. It focuses on cancer care, specifically in prostate, renal or kidney and glioblastoma or brain cancer. Its products include TLX250, TLX591, and TLX101. The company was founded by Andreas Kluge and Christian P. Behrenbruch in November 2015 and is headquartered in Melbourne, Australia. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Loop Industries Insiders Buy Stock, Signal Confidence in Outlook Joby Aviation's Pullback: A Gift for Investors Who See the Future Kohl’s Stock Rebound Faces a Showdown With Short Sellers What to Watch for From D-Wave Now That Earnings Are Done 3 High-Yield Stocks Just Supercharged Their Dividends MarketBeat Week in Review – 08/25 - 08/29 Ollie’s Bargain Outlet: Buy it While It’s Still a Bargain Alphabet’s Resurgence: It's Now a Clear Market Leader Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
